Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TIMOTHY E BYUN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1871545012
CMS profile
356857
Location
ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$6,725.86

235 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $5,060.86 234
Consulting Fee $1,665.00 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $2,072.05 17
PFIZER INC. $536.60 28
Novartis Pharmaceuticals Corporation $486.19 21
Merck Sharp & Dohme LLC $231.31 10
Exelixis Inc. $212.25 7
GlaxoSmithKline, LLC. $203.33 13
E.R. Squibb & Sons, L.L.C. $198.46 18
ABBVIE INC. $190.75 14
Sumitomo Pharma America, Inc. $162.04 8
Janssen Biotech, Inc. $156.38 8
ARRAY BIOPHARMA INC $152.58 8
Genentech USA, Inc. $145.14 5
Daiichi Sankyo Inc. $143.36 5
Astellas Pharma US Inc $139.76 6
Gilead Sciences, Inc. $136.69 6
PharmaEssentia USA Corporation $130.26 4
Takeda Pharmaceuticals U.S.A., Inc. $111.36 4
Celgene Corporation $102.40 4
Eisai Inc. $99.11 4
Karyopharm Therapeutics Inc. $94.02 4
Lilly USA, LLC $80.35 3
GENZYME CORPORATION $78.11 4
Regeneron Healthcare Solutions, Inc. $65.55 2
Stemline Therapeutics Inc. $62.13 3
Incyte Corporation $60.33 3
Ipsen Biopharmaceuticals, Inc $58.37 2
SpringWorks Therapeutics, Inc. $55.96 2
BeiGene USA, Inc. $52.19 2
Genmab U.S., Inc. $49.68 2
Boehringer Ingelheim Pharmaceuticals, Inc. $44.38 1
Bayer Healthcare Pharmaceuticals Inc. $42.84 2
TerSera Therapeutics LLC $37.50 1
TAIHO ONCOLOGY, INC. $33.54 2
Pharmacosmos Therapeutics Inc. $32.36 1
Tempus AI, Inc $29.22 1
PUMA BIOTECHNOLOGY, INC. $28.30 1
EMD Serono, Inc. $28.06 1
Blueprint Medicines Corporation $27.94 1
SOBI, INC $27.88 1
Alexion Pharmaceuticals, Inc. $26.38 1
Coherus Biosciences Inc. $25.32 1
ACCORD HEALTHCARE, INC. $23.96 1
ADC Therapeutics America, Inc. $19.58 1
JAZZ PHARMACEUTICALS INC. $16.06 1
Acrotech Biopharma Inc. $15.83 1

Page 5 of 5; records 201–235 of 235 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TIMOTHY E BYUN

NPI 1871545012 · CMS profile ID 356857

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–235 of 235 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871545012?year=2024&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TIMOTHY E BYUN, NPI 1871545012, CMS profile ID 356857. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–235 of 235 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871545012?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). TIMOTHY E BYUN, NPI 1871545012, CMS profile ID 356857. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–235 of 235 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871545012?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
TIMOTHY E BYUN, NPI 1871545012, CMS profile ID 356857, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–235 of 235 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1871545012?year=2024&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

235 matching records · $6,725.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 235 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–235 of 235.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $15.8102/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103401111 CMS
ABBVIE INC. $2.6702/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103401109 CMS
Daiichi Sankyo Inc. $37.4702/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089405112 CMS
Takeda Pharmaceuticals U.S.A., Inc. $29.1302/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144954463 CMS
PFIZER INC. $18.8202/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131303638 CMS
Novartis Pharmaceuticals Corporation $24.9702/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086758357 CMS
Novartis Pharmaceuticals Corporation $13.3202/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086758361 CMS
PFIZER INC. $25.7902/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131297746 CMS
PFIZER INC. $18.8102/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131284172 CMS
E.R. Squibb & Sons, L.L.C. $7.2302/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101202576 CMS
GlaxoSmithKline, LLC. $13.1002/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115854015 CMS
Janssen Biotech, Inc. $12.7701/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078315882 CMS
Janssen Biotech, Inc. $23.3401/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078315246 CMS
SpringWorks Therapeutics, Inc. $26.2501/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085803282 CMS
ARRAY BIOPHARMA INC $18.1801/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131572517 CMS
Celgene Corporation $33.3301/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101077466 CMS
Novartis Pharmaceuticals Corporation $19.5301/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086758359 CMS
Merck Sharp & Dohme LLC $23.8801/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141803879 CMS
ACCORD HEALTHCARE, INC. $23.9601/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120076374 CMS
Janssen Biotech, Inc. $15.0001/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078315362 CMS
Acrotech Biopharma Inc. $15.8301/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147104748 CMS
Ipsen Biopharmaceuticals, Inc $24.8001/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091965676 CMS
Incyte Corporation $26.2701/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141180276 CMS
ABBVIE INC. $0.9801/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103401105 CMS
ABBVIE INC. $23.9501/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103401107 CMS
PFIZER INC. $0.5001/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131533848 CMS
PFIZER INC. $24.6401/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131533657 CMS
PFIZER INC. $5.9001/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131529721 CMS
PharmaEssentia USA Corporation $34.6301/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137310772 CMS
Gilead Sciences, Inc. $23.5801/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133806135 CMS
AstraZeneca Pharmaceuticals LP $23.2501/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105491679 CMS
Novartis Pharmaceuticals Corporation $11.6001/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086758355 CMS
E.R. Squibb & Sons, L.L.C. $11.6501/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101202566 CMS
E.R. Squibb & Sons, L.L.C. $0.2301/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101202568 CMS
GlaxoSmithKline, LLC. $16.8001/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116370607 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $45,857.71 242
PY2020 $8,207.43 159
PY2021 $8,123.38 221
PY2022 $8,631.42 227
PY2023 $15,051.12 214
PY2024 $6,725.86 235
PY2025 $5,583.21 276

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $236,520.43 59
PY2024 Principal investigator $351,810.22 57
PY2023 Principal investigator $441,384.47 42
PY2022 Principal investigator $137,954.21 31
PY2021 Principal investigator $167,046.51 28
PY2020 Principal investigator $1,455,846.40 41
PY2019 Principal investigator $110,652.36 37

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $9,502.40 12/31/2025 Non-covered Recipient Entity
St. Joseph Hospital-The Center for Cancer Prevention and Treatment
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy No dispute reported 06/30/2026 1232931502
Principal investigator 1 Merck Sharp & Dohme LLC $489.00 12/10/2025 Non-covered Recipient Entity
St. Joseph Hospital-The Center for Cancer Prevention and Treatment
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy No dispute reported 06/30/2026 1232931500
Principal investigator 1 Genentech, Inc. $1,044.00 12/01/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211659291
Principal investigator 1 PFIZER INC. $1,400.00 11/26/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228709212
Principal investigator 1 Genentech, Inc. $478.13 11/25/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
Neoadjuvant NSCLC No dispute reported 06/30/2026 1211659249
Principal investigator 1 Genentech, Inc. $478.13 11/20/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
Neoadjuvant NSCLC No dispute reported 06/30/2026 1211659254
Principal investigator 1 BioNTech SE $1,200.00 10/29/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
BNT122 No dispute reported 06/30/2026 1249017893
Principal investigator 1 BioNTech SE $1,400.00 10/29/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
BNT122 No dispute reported 06/30/2026 1249017895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,800.00 10/29/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253784
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,534.00 10/29/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,550.00 10/29/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,500.00 10/29/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253791
Principal investigator 1 Genentech, Inc. $128.00 10/23/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211659295
Principal investigator 1 Genentech, Inc. $1,078.00 10/22/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659226
Principal investigator 1 Genentech, Inc. $2,124.00 10/22/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659229
Principal investigator 1 Genentech, Inc. $2,500.00 10/10/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
Neoadjuvant NSCLC No dispute reported 06/30/2026 1211659246
Principal investigator 1 Janssen Research & Development, LLC $1,750.00 09/29/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175352100
Principal investigator 1 Genentech, Inc. $1,552.00 09/25/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211659287
Principal investigator 1 Genentech, Inc. $478.13 09/17/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
Neoadjuvant NSCLC No dispute reported 06/30/2026 1211659243
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,000.00 09/15/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190313701
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,831.00 08/26/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190313705
Principal investigator 1 BioNTech SE $1,088.00 07/22/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
BNT-122-01 No dispute reported 06/30/2026 1249017772
Principal investigator 1 Genentech, Inc. $478.13 07/21/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
Neoadjuvant NSCLC No dispute reported 06/30/2026 1211659239
Principal investigator 1 Janssen Research & Development, LLC $31,333.00 07/21/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175352106
Principal investigator 1 Genentech, Inc. $268.00 07/11/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659176
Principal investigator 1 Genentech, Inc. $130.00 07/11/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659181
Principal investigator 1 Genentech, Inc. $2,508.00 07/11/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659185
Principal investigator 1 Genentech, Inc. $2,508.00 07/11/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659188
Principal investigator 1 Genentech, Inc. $130.00 07/11/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659194
Principal investigator 1 Genentech, Inc. $217.47 07/11/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659204
Principal investigator 1 Genentech, Inc. $545.30 07/11/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659207
Principal investigator 1 Genentech, Inc. $268.00 07/11/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659215
Principal investigator 1 Genentech, Inc. $1,500.00 07/11/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659218
Principal investigator 1 Genentech, Inc. $2,500.00 07/11/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659223
Principal investigator 1 Janssen Research & Development, LLC $1,750.00 07/11/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175352132
Principal investigator 1 PFIZER INC. $7,000.00 07/07/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228709210
Principal investigator 1 BioNTech SE $4,000.00 07/04/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
BNT-122-01 No dispute reported 06/30/2026 1249017774
Principal investigator 1 Genentech, Inc. $130.00 07/04/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659196
Principal investigator 1 Genentech, Inc. $2,508.00 07/04/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659200
Principal investigator 1 Genentech, Inc. $267.80 07/04/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211659212
Principal investigator 1 Genentech, Inc. $956.26 06/17/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
Neoadjuvant NSCLC No dispute reported 06/30/2026 1211659232
Principal investigator 1 ABBVIE INC. $1,278.06 06/11/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL THE CENTER FOR CANCER PREVENTION AND TREATMENT ORANGE CA
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1202490851
Principal investigator 1 ABBVIE INC. $750.00 06/11/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL THE CENTER FOR CANCER PREVENTION AND TREATMENT ORANGE CA
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1202490853
Principal investigator 1 BioNTech SE $500.00 06/05/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
BNT-122-01 No dispute reported 06/30/2026 1249017766
Principal investigator 1 Janssen Research & Development, LLC $26,000.00 05/20/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175352066
Principal investigator 1 Janssen Research & Development, LLC $22,471.00 05/20/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175352113
Principal investigator 1 BioNTech SE $202.00 05/15/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
BNT-122-01 No dispute reported 06/30/2026 1249017764
Principal investigator 1 Genentech, Inc. $1,583.00 05/06/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211659283
Principal investigator 1 Janssen Research & Development, LLC $1,600.00 05/05/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175352058
Principal investigator 1 Genentech, Inc. $478.13 04/25/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
Neoadjuvant NSCLC No dispute reported 06/30/2026 1211659235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 04/24/2025 Non-covered Recipient Entity
STJOSEPHHOSPITALOFORANGE
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184189341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/24/2025 Non-covered Recipient Entity
STJOSEPHHOSPITALOFORANGE
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184189343
Principal investigator 1 BioNTech SE $2,991.00 04/08/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
BNT-122-01 No dispute reported 06/30/2026 1249017762
Principal investigator 1 Genentech, Inc. $4,000.00 03/24/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211659280
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $842.14 03/19/2025 Non-covered Recipient Entity
Saint Joseph Hospital
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1235994105
Principal investigator 1 Genentech, Inc. $128.00 03/03/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211659277
Principal investigator 1 BioNTech SE $120.00 01/23/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL OF ORANGE
BNT-122-01 No dispute reported 06/30/2026 1249017738
Principal investigator 1 Novartis Pharmaceuticals Corporation $36,739.00 01/16/2025 Non-covered Recipient Entity
SAINT JOSEPH HOSPITAL ORANGE
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190312629
Principal investigator 1 Novartis Pharmaceuticals Corporation $435.35 01/15/2025 Non-covered Recipient Entity
ST JOSEPH HOSPITAL
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190313703